Enfortumab Vedotin is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody directed against Nectin-4 linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) through a protease-cleavable linker. It is an oncology pharmaceutical product used in targeted cancer therapy.
Enfortumab Vedotin targets Nectin-4, a protein highly expressed in many urothelial cancers. After binding to Nectin-4, the ADC is internalized by the cancer cell and the linker is cleaved, releasing MMAE. MMAE disrupts microtubule networks, resulting in cell-cycle arrest and apoptosis.
Enfortumab Vedotin is a Nectin-4-directed antibody-drug conjugate. It combines the targeting properties of a monoclonal antibody with the cytotoxic activity of MMAE, allowing delivery of the cytotoxic payload to Nectin-4-expressing cells.
It is marketed under the brand name Padcev and is used in combination with other anticancer therapies for specified patients with advanced or metastatic urothelial carcinoma.
Unlike conventional small-molecule APIs, Enfortumab Vedotin is a biological drug substance / antibody-drug conjugate. Its manufacturing and quality control therefore involve specialized biological and bioconjugation processes.
Important quality attributes can include:
Enfortumab Vedotin binds to Nectin-4 on the surface of cancer cells. The ADC is internalized, and enzymatic cleavage of its linker releases MMAE inside the cell. MMAE binds to tubulin and disrupts microtubule formation, leading to cell-cycle arrest and apoptotic cell death.
Enfortumab Vedotin is associated with:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |